Roberta Alfieri
Roberta Alfieri
Associate Professor in General Pathology, University of Parma
Verified email at
Cited by
Cited by
Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer
C Fumarola, MA Bonelli, PG Petronini, RR Alfieri
Biochemical pharmacology 90 (3), 197-207, 2014
Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and …
G Mazzaschi, D Madeddu, A Falco, G Bocchialini, M Goldoni, F Sogni, ...
Clinical cancer research 24 (2), 407-419, 2018
Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells1
M Brigotti, R Alfieri, P Sestili, M Bonelli, PG Petronini, A Guidarelli, ...
The FASEB Journal 16 (3), 365-372, 2002
The translational machinery of human CD4+ T cells is poised for activation and controls the switch from quiescence to metabolic remodeling
S Ricciardi, N Manfrini, R Alfieri, P Calamita, MC Crosti, S Gallo, R Müller, ...
Cell metabolism 28 (6), 895-906. e5, 2018
Hyperosmotic stress response: comparison with other cellular stresses
RR Alfieri, PG Petronini
Pflügers Archiv-European Journal of Physiology 454, 173-185, 2007
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity
C Carmi, A Cavazzoni, V Zuliani, A Lodola, F Bordi, PV Plazzi, RR Alfieri, ...
Bioorganic & medicinal chemistry letters 16 (15), 4021-4025, 2006
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis
RR Alfieri, A Cavazzoni, PG Petronini, MA Bonelli, AE Caccamo, ...
The Journal of Physiology 540 (2), 499-508, 2002
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
A Cavazzoni, MA Bonelli, C Fumarola, S La Monica, K Airoud, R Bertoni, ...
Cancer letters 323 (1), 77-87, 2012
Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer
C Carmi, M Mor, PG Petronini, RR Alfieri
Biochemical pharmacology 84 (11), 1388-1399, 2012
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines
S La Monica, M Galetti, RR Alfieri, A Cavazzoni, A Ardizzoni, M Tiseo, ...
Biochemical pharmacology 78 (5), 460-468, 2009
Tumor-infiltrating lymphocytes and breast cancer: beyond the prognostic and predictive utility
A Ravelli, G Roviello, D Cretella, A Cavazzoni, A Biondi, MR Cappelletti, ...
Tumor Biology 39 (4), 1010428317695023, 2017
Combined inhibition of CDK4/6 and PI3K/AKT/mTOR pathways induces a synergistic anti-tumor effect in malignant pleural mesothelioma cells
MA Bonelli, G Digiacomo, C Fumarola, R Alfieri, F Quaini, A Falco, ...
Neoplasia 19 (8), 637-648, 2017
Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents
SA Al-Trawneh, JA Zahra, MR Kamal, MM El-Abadelah, F Zani, M Incerti, ...
Bioorganic & medicinal chemistry 18 (16), 5873-5884, 2010
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress
RR Alfieri, MA Bonelli, A Cavazzoni, M Brigotti, C Fumarola, P Sestili, ...
The Journal of physiology 576 (2), 391-401, 2006
Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis
C Fumarola, S La Monica, RR Alfieri, E Borra, GG Guidotti
Cell Death & Differentiation 12 (10), 1344-1357, 2005
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
S La Monica, D Cretella, M Bonelli, C Fumarola, A Cavazzoni, ...
Journal of Experimental & Clinical Cancer Research 36, 1-12, 2017
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells
D Cretella, A Ravelli, C Fumarola, S La Monica, G Digiacomo, ...
Journal of Experimental & Clinical Cancer Research 37, 1-12, 2018
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines
A Cavazzoni, RR Alfieri, C Carmi, V Zuliani, M Galetti, C Fumarola, ...
Molecular cancer therapeutics 7 (2), 361-370, 2008
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signaling
C Fumarola, C Caffarra, S La Monica, M Galetti, RR Alfieri, A Cavazzoni, ...
Breast cancer research and treatment 141, 67-78, 2013
Irreversible inhibition of epidermal growth factor receptor activity by 3-aminopropanamides
C Carmi, E Galvani, F Vacondio, S Rivara, A Lodola, S Russo, S Aiello, ...
Journal of medicinal chemistry 55 (5), 2251-2264, 2012
The system can't perform the operation now. Try again later.
Articles 1–20